SPECIAL FEATURES

CCR 20th Anniversary Commentary

493  CCR 20th Anniversary Commentary: Radioactive Drones for B-cell Lymphoma
Susan J. Knox and Ronald Levy

CCR Translations

495  Novel Targets in Head and Neck Cancer: Should We Be Optimistic?
Gabriel S. Krigsfeld and Christine H. Chung
See related article, p. 632

Molecular Pathways

Michelle Cicchini, Vassiliki Karantza, and Bing Xia

505  Molecular Pathways: Novel Approaches for Improved Therapeutic Targeting of Hedgehog Signaling in Cancer Stem Cells
Verline Justilien and Alan P. Fields

Special Report

514  Electronic Nicotine Delivery Systems: A Policy Statement from the American Association for Cancer Research and the American Society of Clinical Oncology

Review

526  HER2 as a Therapeutic Target in Head and Neck Squamous Cell Carcinoma
Netanya I. Pollock and Jennifer R. Grandis

CANCER THERAPY: CLINICAL

534  Persistence of CTL Clones Targeting Melanocyte Differentiation Antigens Was Insufficient to Mediate Significant Melanoma Regression in Humans

544  Phase II Clinical and Exploratory Biomarker Study of Dacomitinib in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck
Han Sang Kim, Hyorange Ju Kwon, Inkyung Jung, Mi Ran Yun, Myung-Ju Ahn, Byung Woong Kang, Jong-Mu Sun, Sung Bae Kim, Dok-Hyun Yoon, Keon Uk Park, Se-Hoon Lee, Yoon Woo Koh, Se Hun Kim, Eun Chang Choi, Dong Hoe Koo, Jin Hee Sohn, Bomi Kim, Nak-Jung Kwon, Hwan Jung Yun, Min Goo Lee, Ji Hyun Lee, Tae-Min Kim, Hye Ryun Kim, Joo Hang Kim, Soonmyung Paik, and Byoung Chul Cho

553  First-in-Human Dose Study of the Novel Transforming Growth Factor-β Receptor 1 Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma

PERSONALIZED MEDICINE AND IMAGING

561  The High-Dose Aldesleukin "Select" Trial: A Trial to Prospectively Validate Predictive Models of Response to Treatment in Patients with Metastatic Renal Cell Carcinoma
High HER2 Expression Correlates with Response to the Combination of Lapatinib and Trastuzumab
Maurizio Scaltriti, Paolo Nuciforo, Ian Bradbury, Jeff Sperinde, Dominique Agbor-Tah, Christine Campbell, Ahmed Chenna, John Winslow, Violeta Serra, Josep Lluís Parra, Ludmila Prudkin, José Jimenez, Claudia Aura, Nadia Harbeck, Lajos Pusztai, Catherine Ellis, Holger Eichmann, Joaquín Arribas, Javier Cortes, Evandro de Azambuja, Martine Piccart, and José Baselga

Optical Mammography Using Diffuse Optical Spectroscopy for Monitoring Tumor Response to Neoadjuvant Chemotherapy in Women with Locally Advanced Breast Cancer

A Five-Gene Hedgehog Signature Developed as a Patient Preselection Tool for Hedgehog Inhibitor Therapy in Medulloblastoma

Interobserver Agreement in Describing the Ultrasound Appearance of Adnexal Masses and in Calculating the Risk of Malignancy Using Logistic Regression Models
Povilas Sladkevicius and Lil Valentin

Differential Platelet Levels Affect Response to Taxane-Based Therapy in Ovarian Cancer
Justin Botsford-Miller, Hyun-Jin Choi, Heather J. Dalton, Rebecca L. Stone, Min Soon Cho, Monika Haemmerle, Alpa M. Niek, Sunila Pradeep, Behrouz Zand, Rebecca A. Previs, Chad V. Pecot, Erin King Crane, Wei Hu, Susan K. Lutgendorf, Vahid Afshar-Kharghan, and Anil K. Sood

Podoplanin-Positive Cancer-Associated Fibroblasts in the Tumor Microenvironment Induce Primary Resistance to EGFR-TKIs in Lung Adenocarcinoma with EGFR Mutation
Tatsuya Yoshida, Genichiro Ishii, Koichiro Goto, Shinya Neri, Hiroko Hashimoto, Kiyotaka Yoh, Seiji Niho, Shigeru Umemura, Shingo Matsumoto, Hironobu Ohmatsu, Chisato Iida, Akio Niimi, Kanji Nagai, Yuichiro Ohe, and Atsushi Ochiai
LETTERS TO THE EDITOR

658  DNA Repair Mutations and Outcomes in Ovarian Cancer—Letter
Robert A. Soslow

659  DNA Repair Mutations and Outcomes in Ovarian Cancer—Response
Elizabeth M. Swisher, Barbara M. Norquist, Kathryn P. Pennington, Mara H. Rendi, and Rochelle L. Garcia

CORRECTIONS

660  Correction: First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic Cancer

661  Correction: HDM2 Regulation by AURKA Promotes Cell Survival in Gastric Cancer

662  Correction: Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors

ABOUT THE COVER

The cover shows NFκB translocation in tumor-infiltrating lymphocytes from a patient with metastatic melanoma. Immunocytochemistry staining shows NFκB (p65) translocation (red is nucleus; green is NFκB, and yellow is overlay [translocation]) in the nucleus of tumor-infiltrating lymphocytes expanded with IL-2 and an anti-4-1BB antibody. For details, see the article by Chacon and colleagues on page 611 of this issue.